Founded on Science.
Focused on Patients.

Discovering, Developing & Commercializing Targeted Small Molecule Drugs in Cancer

A Year of
Significant
Progress

Read Ron Squarer's
letter to shareholders

Binimetinib

Learn more
about our Phase 3
cancer trials

Encorafenib

Learn more about
our Phase 3
cancer program